Spero Therapeutics, Inc. (SPRO) stock
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.00−0.00 (-0.01%)
Close on Nov 13, 2026Market cap $58.23MP/E –Yield –
Spero Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Spero Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $15.13M, down 75.5% year over year. For fiscal 2025 it was $38.47M, down 60.2% from the year before. Over ten years it grew 13.2% a year on average. The highest annual figure on record is $96.76M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.47M | -60.2% |
| FY2024 | Dec 31, 2024 | $96.76M | +88.1% |
| FY2023 | Dec 31, 2023 | $51.44M | +8.1% |
| FY2022 | Dec 31, 2022 | $47.59M | -26.2% |
| FY2021 | Dec 31, 2021 | $64.53M | -3.7% |
| FY2020 | Dec 31, 2020 | $67.00M | +1.9% |
| FY2019 | Dec 31, 2019 | $65.78M | +94.1% |
| FY2018 | Dec 31, 2018 | $33.89M | +3.1% |
| FY2017 | Dec 31, 2017 | $32.87M | +24.8% |
| FY2016 | Dec 31, 2016 | $26.33M | +136.7% |
| FY2015 | Dec 31, 2015 | $11.13M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.20M | -62.8% |
| Q2 FY2026 | Jun 30, 2026 | $3.43M | -67.8% |
| Q1 FY2026 | Mar 31, 2026 | $2.91M | -78.6% |
| Q4 FY2025 | Dec 31, 2025 | $5.59M | -80.6% |
| Q3 FY2025 | Sep 30, 2025 | $8.60M | -68.0% |
| Q2 FY2025 | Jun 30, 2025 | $10.67M | -55.0% |
| Q1 FY2025 | Mar 31, 2025 | $13.61M | -21.5% |
| Q4 FY2024 | Dec 31, 2024 | $28.84M | +74.2% |
| Q3 FY2024 | Sep 30, 2024 | $26.86M | +63.9% |
| Q2 FY2024 | Jun 30, 2024 | $23.73M | +149.5% |
| Q1 FY2024 | Mar 31, 2024 | $17.33M | +93.0% |
| Q4 FY2023 | Dec 31, 2023 | $16.56M | +9.7% |
| Q3 FY2023 | Sep 30, 2023 | $16.39M | +122.7% |
| Q2 FY2023 | Jun 30, 2023 | $9.51M | +16.4% |
| Q1 FY2023 | Mar 31, 2023 | $8.98M | -47.1% |
| Q4 FY2022 | Dec 31, 2022 | $15.09M | -12.4% |
| Q3 FY2022 | Sep 30, 2022 | $7.36M | -49.0% |
| Q2 FY2022 | Jun 30, 2022 | $8.17M | -43.5% |
| Q1 FY2022 | Mar 31, 2022 | $16.97M | -7.8% |
| Q4 FY2021 | Dec 31, 2021 | $17.23M | +30.4% |
| Q3 FY2021 | Sep 30, 2021 | $14.44M | -18.5% |
| Q2 FY2021 | Jun 30, 2021 | $14.46M | -7.6% |
| Q1 FY2021 | Mar 31, 2021 | $18.40M | -9.9% |
| Q4 FY2020 | Dec 31, 2020 | $13.21M | -48.7% |
| Q3 FY2020 | Sep 30, 2020 | $17.71M | -4.3% |
| Q2 FY2020 | Jun 30, 2020 | $15.66M | +30.2% |
| Q1 FY2020 | Mar 31, 2020 | $20.44M | +114.5% |
| Q4 FY2019 | Dec 31, 2019 | $25.73M | +181.9% |
| Q3 FY2019 | Sep 30, 2019 | $18.50M | +118.6% |
| Q2 FY2019 | Jun 30, 2019 | $12.03M | +63.1% |
| Q1 FY2019 | Mar 31, 2019 | $9.53M | +6.7% |
| Q4 FY2018 | Dec 31, 2018 | $9.13M | -27.0% |
| Q3 FY2018 | Sep 30, 2018 | $8.46M | +22.4% |
| Q2 FY2018 | Jun 30, 2018 | $7.37M | -1.1% |
| Q1 FY2018 | Mar 31, 2018 | $8.93M | +48.8% |
| Q4 FY2017 | Dec 31, 2017 | $12.50M | +80.5% |
| Q3 FY2017 | Sep 30, 2017 | $6.91M | – |
| Q2 FY2017 | Jun 30, 2017 | $7.46M | – |
| Q1 FY2017 | Mar 31, 2017 | $6.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.93M | – |
See a number that looks wrong?